Rosen Law Firm reminds purchasers of ADMA Biologics securities between August 9, 2024 and March 25, 2026 of the August 10, 2026 lead plaintiff deadline in a securities class action first filed by the firm. The lawsuit alleges that ADMA Biologics made materially false and misleading statements and failed to disclose an undisclosed related party transaction, channel stuffing to inflate revenue, and inadequate internal controls. Investors who purchased ADMA Biologics securities during the class period may be entitled to compensation through a contingency fee arrangement. Rosen Law Firm highlights its track record, including the largest securities class action settlement against a Chinese company and over $438 million recovered for investors in 2019.
ADMA Biologics IncSecurities class action lawsuit alleging false statements, undisclosed related party transaction, channel stuffing, and inadequate internal controls.